Singapore markets closed

Organogenesis Holdings Inc. (ORGO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.2650+0.0250 (+0.77%)
As of 10:54AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close3.2400
Open3.2900
Bid3.2600 x 900
Ask3.2700 x 1300
Day's range3.2100 - 3.2900
52-week range3.0800 - 13.6050
Volume94,032
Avg. volume1,155,933
Market cap427.349M
Beta (5Y monthly)1.74
PE ratio (TTM)6.05
EPS (TTM)0.5400
Earnings date07 Nov 2022 - 11 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.00
  • Motley Fool

    Why Organogenesis Stock Is Tumbling Today

    Shares of Organogenesis Holdings (NASDAQ: ORGO) fell by 19.6% as of 2:45 p.m. ET on Wednesday after the wound care company reported worse-than-anticipated Q2 earnings and also slashed its guidance for the rest of 2022. Its net revenue for the quarter was $121.4 million, a decline of 1% year over year, and its net income collapsed by 58% year over year to reach $8.7 million. For its fiscal 2022 earnings guidance, management now expects net revenue of between $465 million and $490 million, whereas in its initial guidance, it expected between $485 million and $515 million.

  • Motley Fool

    Organogenesis Holdings Inc. (ORGO) Q2 2022 Earnings Call Transcript

    Good afternoon, ladies and gentlemen, and welcome to the second quarter 2022 earnings conference call for Organogenesis Holdings Inc. [Operator instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Let me start with a brief agenda of what we'll be covering during our prepared remarks.

  • Zacks

    Organogenesis (ORGO) Tops Q2 Earnings and Revenue Estimates

    Organogenesis (ORGO) delivered earnings and revenue surprises of 12.50% and 0.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?